erlotinib tarbis 150 mg film-coated tablets
jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 150 mg - antineoplastic agents
erlotinib taro 100 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 100 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
erlotinib taro 150 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 150 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
erlotinib taro 25 mg
taro international ltd, israel - erlotinib as hydrochloride - film coated tablets - erlotinib as hydrochloride 25 mg - erlotinib - non-small cell lung cancer (nsclc): erlotinib taro is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations. erlotinib taro is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations and stable disease after first-line chemotherapy. erlotinib taro is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.pancreatic cancer: erlotinib taro is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
mirata 100mg f.c tab 100 mg
شركة أدوية الحكمة - hikma pharmaceuticals - erlotinib 100 mg - 100 mg
mirata 150mg f.c tab 150 mg
شركة أدوية الحكمة - hikma pharmaceuticals - erlotinib 150 mg - 150 mg
mirata 25mg f.c tab 25 mg
شركة أدوية الحكمة - hikma pharmaceuticals - erlotinib 25 mg - 25 mg
tarceva 100 mg
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - erlotinib 100 mg - 100 mg
tarceva f.c.tablet 150 mg
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - erlotinib 150 mg - 150 mg
varlota 100 mg film-coated tablets
cherubino limited delf building, sliema road, gzira, gzr 1637, malta - erlotinib hydrochloride - film-coated tablet - erlotinib hydrochloride 100 mg - antineoplastic agents